|
AI value for Nitroso Folic acid
|
|
4
|
1387
|
February 26, 2024
|
|
AI for en Indole struktur (N-Nitroso melatonin)
|
|
8
|
1134
|
February 20, 2024
|
|
Risk characterization of N-nitrosodimethylamine in pharmaceuticals -Pub
|
|
6
|
540
|
February 16, 2024
|
|
Developing and validating read-across workflows that enable decision making for toxicity and potency: Case studies with N-nitrosamines -Pub
|
|
4
|
352
|
February 14, 2024
|
|
Nitrosamines Severity (impact) - a quantitative model proposal?
|
|
3
|
742
|
February 12, 2024
|
|
Defining nitrosamine acceptable intake based on technical feasibible limit rather than CPCA
|
|
6
|
299
|
February 11, 2024
|
|
N- nitroso Nitazoxanide
|
|
1
|
242
|
February 8, 2024
|
|
TGA (Australia) :australia: Updates Published Acceptable Intakes
|
|
3
|
538
|
February 7, 2024
|
|
Visualization of Categorized Compounds by CPCA
|
|
56
|
5908
|
February 5, 2024
|
|
Aromatic nitrogen "Is it possible for aromatic nitrogen to convert nitrosamine?"- Indole
|
|
10
|
1365
|
February 2, 2024
|
|
Nitrosamine Impurities in Topical Drug Product
|
|
3
|
430
|
February 3, 2024
|
|
N-Nitroso Metformin
|
|
8
|
868
|
January 29, 2024
|
|
N-nitroso Vonoprazan AI 96 ng/day- FDA
|
|
5
|
2035
|
January 29, 2024
|
|
Limit for NDSRI
|
|
3
|
827
|
January 29, 2024
|
|
Updated EMA-Acceptable intakes (AIs) established for N-nitrosamines
|
|
20
|
2954
|
January 29, 2024
|
|
How to identify NDSRI for an API
|
|
5
|
505
|
January 24, 2024
|
|
The comprehensive prediction of carcinogenic potency and tumorigenic dose (TD50) for two problematic N-nitrosamines in food: NMAMPA and NMAMBA using toxicology in silico methods -Pub
|
|
0
|
180
|
January 23, 2024
|
|
A quick (dumb) question
|
|
10
|
796
|
January 22, 2024
|
|
N-nitroso-Impurity C in Metamizol Drug product
|
|
11
|
1063
|
January 22, 2024
|
|
Confidence score calculation for the carcinogenic potency categorization approach (CPCA) predictions for N-nitrosamines
|
|
5
|
1003
|
January 11, 2024
|
|
Nitroso-melatonin
|
|
3
|
508
|
January 4, 2024
|
|
Calculation of allowable limit in drug product with two API's
|
|
3
|
474
|
January 4, 2024
|
|
AI limit for N-nitroso betahistine?
|
|
26
|
2862
|
January 4, 2024
|
|
NDSRI in metronidazole
|
|
1
|
559
|
December 28, 2023
|
|
What should be the AI for N-Nitrosamines where CPCA doesn't apply (e.g. N-Nitroso Pyrrole Analogues where alpha carbon directly double bonded to hetero atom)?
|
|
1
|
628
|
December 27, 2023
|
|
Calculation of Nitrosamines AI not covered by CPCA
|
|
3
|
617
|
December 20, 2023
|
|
Australia TGA - postpone until end of Jun 2024 NTTP 37ng/day
|
|
0
|
312
|
December 15, 2023
|
|
Updated FDA list of published limits
|
|
15
|
2465
|
December 15, 2023
|
|
Nitrosamine due to preservative in ophthalmic
|
|
3
|
554
|
December 8, 2023
|
|
Control of NDSRIs impurity at Drug Substance (API) specification
|
|
8
|
918
|
December 5, 2023
|